Norway’s MATRIX program is integrating rapid nanopore-sequencing into the country’s national precision diagnostics infrastructure to speed CNS tumor classification. Oxford Nanopore said the rollout is based on a Phase 1 clinical evaluation of 50 CNS tumor samples using an assay developed at Oslo University Hospital, showing strong agreement with established diagnostic methods. The program will start by integrating at Oslo University Hospital, Haukeland University Hospital, and St. Olavs Hospital, with expansion planned after initial deployment. Oxford Nanopore also said Oslo University Hospital plans to submit documentation required under the EU In Vitro Diagnostic Regulation (IVDR) by year-end. MATRIX is also expected to broaden nanopore use beyond classification toward variant detection, copy number benchmarking, single-cell transcriptomics, and genome-wide methylation, subject to workflow integration.